ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

30 May 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

19 May 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

10 May 2023 07:25:00 By Nasdaq GlobeNewswire

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

10 May 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

26 Apr 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

04 Apr 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

16 Mar 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

14 Mar 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

08 Mar 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial

16 Feb 2023 16:44:36 By Nasdaq GlobeNewswire

Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model

30 Jan 2023 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

25 Jan 2023 07:25:00 By Nasdaq GlobeNewswire